NSE与视频脑电图在儿童热性惊厥的相关性研究

Objective: To evaluate the diagnostic value of serum neuron specific enolase and Video EEG inFebrile Convulsion of childen. Method:Serum NSE was detected by RIA on the first day and the seventh day afterseizure in 40 children with simple febrile convulsion and 18 with complex febrile convulsion. Video EEG was per-formed at 1st, 7th and 30th day in all the patients. Results: There were significant differences between NSE levels at24th hour and on 7th day after convulsion (P<0.01). NSE concentrations in patients with SFC and CFC were also     

Endocrine differentiation of extra-pulmonary small cell carcinoma demonstrated by immunohistochemistry using antibodies to PGP 9.5, neuron-specific enolase and the C-flanking peptide of human pro-bombesin

Several recent studies have confirmed the endocrine nature of small cell carcinoma of the lung. In extra-pulmonary sites, small cell 'undifferentiated' carcinomas have classical morphological features similar to their pulmonary counterpart. We therefore investigated, using immunocytochemistry, the possibility that the non-pulmonary neoplasms may also be endocrine in nature. Sections of 29 small cell carcinomas from oesophagus, stomach, larynx, colon and urinary bladder were immunostained using antisera to protein gene product 9.5 (PGP 9.5), neuron-specific enolase (NSE), cytokeratin, leucocyte common antigen and peptides including bombesin, the C-flanking peptide of human probombesin, adrenocorticotrophic hormone, neurotensin, calcitonin and pancreatic polypeptide. All the tumours showed immunoreactivity for at least one of the two general endocrine markers PGP 9.5 and NSE. Twenty-three of the 29 cases were immunoreactive for PGP 9.5, 27 for NSE. All were positive for cytokeratin and negative for leucocyte common antigen. Of the regulatory peptides, immunoreactivity was obtained with antisera to bombesin (one case), the C-flanking peptide of human pro-bombesin (14 cases), adrenocorticotrophic hormone (one case) and calcitonin (three cases). No PGP 9.5-, NSE- or peptide-like immunoreactivity was detected in 25 control tumours from similar sites, including lymphomas and poorly differentiated tumours. These results suggest that non-pulmonary small cell carcinoma has an endocrine character.     

肺癌患者化疗前后NSE、SIL-2R和TNF测定的临床意义

目的:探讨33例肺癌患者中28人化疗前后血清中NSE、TNF含量的变化。方法:应用放射免疫分析检测33例肺癌患者化疗前后血清NSE和TNF含量,酶联免疫分析测定SIL-2R含量并与30名正常健康人作比较。结果:肺癌患者化疗前血清中NSE、SIL-2R和TNF含量均非常显著地高于正常人组(P<0.01)。化疗后,6个月在未复发的20例中明显下降但仍高于对照组,而复发的8例,其数值又回升至化疗前水平(P<0.05)。结论:检测肺癌患者血清NSE、SIL-2R和TNF含量的变化可作为诊断和疗效观察的参考。     

联合检测NSE、S100B、hs-CRP及NIHSS评分对急性脑梗死患者病情严重程度的评估价值

目的探讨联合检测神经元特异性烯醇化酶(NSE)、 S100B、超敏C-反应蛋白(hs-CRP)及美国国立卫生研究院卒中量表(NIHSS)评分对急性脑梗死患者病情严重程度的评估价值。方法选取我院2019年1月至2020年3月收治的急性脑梗死患者80例,依据改良Rankin量表(mRS)评分将其分为重度组(mRS评分≥3分,n=36)及轻度组(mRS评分<3分,n=44);另选取同期在我院行健康体检的40例患者作为健康组。比较三组的NSE、 S100B、 hs-CRP及NIHSS评分。结果重度组的NSE、 S100B、 hs-CRP、 NIHSS评分均高于轻度组及健康组(P <0.05);Pearson分析显示,NSE、 S100B、 hs-CRP及NIHSS评分与急性脑梗死病情严重程度呈正相关(r>0, P <0.05)。结论 NSE、 S100B、 hs-CRP及NIHSS评分与急性脑梗死患者病情严重程度呈正相关,联合检测具有客观性。     

Blood biomarkers of mild traumatic brain injury: State of art

BackgroundMild traumatic brain injury (mTBI) is one of the most common causes of emergency department visits around the world. Up to 90% of injuries are classified as mTBI. Cranial computed tomography (CCT) is a standard diagnosis tool to identify intracranial complications in adults with mTBI. Alternatively, children can be admitted for inpatient observation with CCT scans performed only on those with clinical deterioration. The use of blood biomarkers is a supplementary tool for identifying patients at risk of intracerebral lesions who may need imaging.MethodWe realised a bibliographic state of art providing a contemporary clinical and laboratory framework for blood biomarker testing in mTBI management.ResultsThe S100B protein is the only biomarker that can be used today in the clinical routine for management of mTBI with appropriate evidence-based medicine. Due to its excellent negative predictive value, S100B protein is an alternative choice to CCT scanning for mTBI management with considered, consensual and pragmatic use. In this state of art, we propose points to help clinicians and clinical pathologists use serum S100B protein in the clinical routine. A state of art on the different biomarkers (GFAP, UCH-L1, NF [H or L], tau, H-FABP, SNTF, NSE, miRNAs, MBP) is also conducted. Some of these other biomarkers, used alone (GFAP, UCH-L1) or in combination (GFAP + H-FABP ± S100B ± IL10) can improve the specificity of S100B.ConclusionUsing a bibliographic state of art, we highlighted the added values of the blood biomarkers for the clinical management of mTBI.     

血清中NSE水平在晚期NSCLC化疗中的临床意义

目的：探讨治疗前血清中神经特异性烯醇化酶(NSE)水平对晚期非小细胞肺癌(NSCLC)近期化疗疗效及远期生存率的影响。方法：用放射免疫法检测145例NSCLC治疗前血清中NSE水平，评价3周期化疗后的疗效，随访生存率。结果：NSE阳性组其近期化疗有效率高(60．1％)，疗效持续时间短(2．0个月)，1年生存率低(15．3％)，NSE阴性组其近期化疗有效率低(40．7％)．疗效持续时间长(5．9个月)，1年生存率高(40．7％)。结论：血清NSE水平可作为预测晚期NSCLC患者预后的有效指标之一。     

胸水中CEA CYFRA21-1 NSE和LDH对肺癌的临床诊断

目的:探讨CEA、CYFRA21-1、NSE、LDH水平对癌性胸水的诊断价值。方法:采用电化学发光方法检测胸水中的CEA、CYFRA21-1和NSE,采用酶法检测LDH。结果:恶性胸水的CEA、CYFRA21-1、NSE、LDH水平明显高于良性胸水(P<0.01),肺腺癌CEA明显高于鳞癌和小细胞肺癌(P<0.01),肺鳞癌CYFRA21-1水平明显高于腺癌(P<0.05)和小细胞肺癌(P<0.01),小细胞肺癌NSE明显高于鳞癌(P<0.01)。4项标志物联合检测的敏感性、准确性均比单项检测高。结论:联合检测胸水中的CEA、CYFRA21-1、NSE和LDH对肺癌的诊断具有重要的临床意义。     

原发性肺癌患者外周血肿瘤标记物联合检测的临床意义

目的探讨外周血CEA、CYFRA21-1、NSE联合检测对原发性肺癌的诊断、病理分型、分期和疗效判断的临床应用价值。方法采用放射免疫技术,检测72例原发性肺癌患者化学治疗前后、38例良性肺部疾病患者及30例健康人血清CEA、CYFRA21-1、NSE水平。结果肺癌组治疗前CEA、CYFRA21-1、NSE水平显著高于良性肺部疾病组及正常对照组(P均<0.01),且不同病理类型肺癌3种肿瘤标记物的水平有显著性差异。3种肿瘤标记物联合检测与各单项指标检测比较,对肺癌诊断的敏感性显著增高(P<0.01),肺癌NSE检出阳性率最高(63.9%),但特异性有所下降。肺癌组化疗有效者3种肿瘤标记物水平显著下降,病情稳定和进展者三者水平无变化或升高。结论血清CEA、CYFRA21-1、NSE联合检测用于肺癌的诊断有较好的临床参考价值,并有助于肺癌病理类型的评估,亦可作为肺癌病情监测和疗效判断方面有价值的指标。     

高渗盐水治疗重型颅脑损伤后颅内压与NSE的变化及临床意义

目的探讨经高渗盐水治疗后患者重型颅脑损伤不同时间颅内压的变化及血清神经元特异性烯醇化酶(NSE)变化及其临床意义。方法收集我科2015年1月~2016年12月符合重型颅脑损伤诊断标准的患者90例,随机将患者均分为7.5%高渗盐水(HTS)组和甘露醇(M)组,分别用高渗盐水和甘露醇进行脱水降颅压治疗,分别测量患者0 d(用药前)、1 d、3 d、5 d、7 d颅内压值及血清NSE含量,并对两组组内及组间检测结果进行统计学分析。结果高渗盐水治疗组中颅内压较平稳,0 d(用药前)、1 d、3 d、5 d、7 d颅内压分别为(13.51±1.24)mm Hg、(13.75±1.11)mm Hg、(15.23±1.18)mm Hg、(14.84±0.88)mm Hg、(12.28±0.81)mm Hg,而甘露醇治疗组中颅内压波动较大,0 d、1 d、3 d、5 d、7 d颅内压分别为(13.97±1.27)mm Hg、(14.02±1.18)mm Hg、(19.02±1.25)mm Hg、(17.79±0.96)mm Hg、(14.06±0.88)mm Hg;高渗盐水治疗组0 d(用药前)、1 d、3 d、5 d、7 d中血清NSE的量分别是(11.51±1.54)ng/m L、(12.16±1.81)ng/m L、(19.51±1.47)ng/m L、(16.32±1.36)ng/m L、(13.19±1.36)ng/m L;甘露醇治疗组0 d、1 d、3 d、5 d、7 d血清NSE含量分别是(12.24±1.69)ng/m L、(24.21±2.04)ng/m L、(45.31±1.32)ng/m L、(28.34±1.41)ng/m L、(24.13±1.37)ng/m L。结果显示高渗盐水能有效且平稳降低颅内压,两组颅内压变化无明显差异(P0.05),两组组内各时间点颅内压变化差异无统计学意义(P0.05)。甘露醇治疗组各时间点血清NSE含量明显高于高渗盐水治疗组,两组各时间点血清NSE含量有显著差异(P0.05)。两组治疗前GCS评分无明显差异,治疗后随访6个月可见HTS组预后较M组明显好,差异有统计学意义(P0.05)。结论高渗盐水能有效且平稳地降低重型颅脑外伤后颅内压,减轻患者的继发性脑损伤,减少颅脑损伤后NSE含量,并能更有效地改善患者预后。